Imipenem-cilastatin as initial therapy for febrile cancer patients

G. P. Bodey, M. E. Alvarez, P. G. Jones, K. V. Rolston, L. Steelhammer, V. Fainstein

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number2
StatePublished - 1986

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Imipenem-cilastatin as initial therapy for febrile cancer patients'. Together they form a unique fingerprint.

Cite this